journal article·2020-09-02Open access

Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications

Kathryn M. Moore, Cole J. Batty, Rebeca T. Stiepel, Christopher J. Genito, Eric M. Bachelder, Kristy M. Ainslie

ACS Applied Materials & Interfaces· Volume 12· Issue 35

Abstract

Previously, high-aspect- ratio ribbon-like microconfetti (MC) composed of acetalated dextran (Ace-DEX) have been shown to form a subcutaneous depot for sustained drug release. In this study, MC were explored as an injectable vaccine platform. Production of MC by electrospinning followed by high-shear homogenization allowed for precise control over MC fabrication. Three distinct sizes of MC, small (0.67 × 10.2 μm2), medium (1.28 × 20.7 μm2), and large (5.67 × 90.2 μm2), were fabricated and loaded with the adjuvant, resiquimod. Steady release rates of resiquimod were observed from MC, indicating their ability to create an immunostimulatory depot in vivo. Resiquimod-loaded MC stimulated inflammatory cytokine production in bone marrow-derived dendritic cells without incurring additional cytotoxicity in vitro. Interestingly, even medium and large MC were able to be internalized by antigen-presenting cells and facilitate antigen presentation when ovalbumin was adsorbed onto their surface. After subcutaneous injection in vivo with adsorbed ovalbumin, blank MC of all sizes were found to stimulate a humoral response. Adjuvant activity of resiquimod was enhanced by loading it into MC and small- and medium-sized MC effectively induced a Th1-skewed immune response. Antigen co-delivered with adjuvant-loaded MC of various sizes illustrates a new potential vaccine platform.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Microbial infections and disease research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina 27515, United States

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 4211 Marsico Hall, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States

Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27516, United States

Funding

University of North Carolina at Chapel Hill · National Institute of Allergy and Infectious Diseases · Division of Graduate Education · North Carolina Biotechnology Center

References (57)

Show source-provided references
1. 10.1016/j.vaccine.2013.05.00710.1016/j.vaccine.2013.05.007 ↗
2. 10.1016/j.vaccine.2019.04.05510.1016/j.vaccine.2019.04.055 ↗
3. 10.1016/j.vaccine.2011.09.06110.1016/j.vaccine.2011.09.061 ↗
4. 10.1016/j.vaccine.2011.01.01110.1016/j.vaccine.2011.01.011 ↗
5. 10.1016/s0167-4889(01)00182-310.1016/s0167-4889(01)00182-3 ↗
6. 10.1016/j.coi.2017.06.00510.1016/j.coi.2017.06.005 ↗
7. 10.1586/erv.11.2610.1586/erv.11.26 ↗
8. 10.1006/cimm.1998.140610.1006/cimm.1998.1406 ↗
9. 10.1002/adhm.20160064210.1002/adhm.201600642 ↗
10. 10.1007/s11095-013-0975-x10.1007/s11095-013-0975-x ↗
11. 10.1016/j.ijpharm.2015.09.05910.1016/j.ijpharm.2015.09.059 ↗
12. 10.1158/2326-6066.CIR-14-020210.1158/2326-6066.CIR-14-0202 ↗
13. 10.1016/j.vaccine.2004.01.03710.1016/j.vaccine.2004.01.037 ↗
14. 10.4049/jimmunol.090147410.4049/jimmunol.0901474 ↗
15. 10.4161/hv.3440810.4161/hv.34408 ↗
16. 10.4161/biom.1.1.1627710.4161/biom.1.1.16277 ↗
17. 10.1016/j.jconrel.2011.06.00810.1016/j.jconrel.2011.06.008 ↗
18. 10.1002/adhm.20170146910.1002/adhm.201701469 ↗
19. 10.1016/j.biomaterials.2018.01.00410.1016/j.biomaterials.2018.01.004 ↗
20. 10.1021/bm501166j10.1021/bm501166j ↗
21. 10.1016/j.biomaterials.2011.11.06810.1016/j.biomaterials.2011.11.068 ↗
22. 10.1177/088532821770413910.1177/0885328217704139 ↗
23. 10.1002/bit.2653210.1002/bit.26532 ↗
24. 10.1038/nbt.307110.1038/nbt.3071 ↗
25. 10.1002/adhm.20160116010.1002/adhm.201601160 ↗
26. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
27. 10.1021/acsnano.6b0734310.1021/acsnano.6b07343 ↗
28. 10.1002/adhm.20180034110.1002/adhm.201800341 ↗
29. 10.1007/s11095-016-1936-y10.1007/s11095-016-1936-y ↗
30. 10.1021/acs.molpharmaceut.7b0111410.1021/acs.molpharmaceut.7b01114 ↗
31. 10.1021/acsami.0c0410210.1021/acsami.0c04102 ↗
32. 10.1021/acs.chemrev.6b0053210.1021/acs.chemrev.6b00532 ↗
33. 10.1073/pnas.090159210610.1073/pnas.0901592106 ↗
34. 10.1016/j.jconrel.2018.09.02010.1016/j.jconrel.2018.09.020 ↗
35. 10.1021/mp300509810.1021/mp3005098 ↗
36. 10.1021/am300888810.1021/am3008888 ↗
37. 10.1038/3258810.1038/32588 ↗
38. 10.1073/pnas.130500011010.1073/pnas.1305000110 ↗
39. 10.1016/j.jconrel.2015.09.06910.1016/j.jconrel.2015.09.069 ↗
40. 10.4161/hv.2881710.4161/hv.28817 ↗
41. 10.1007/s11095-008-9626-z10.1007/s11095-008-9626-z ↗
42. 10.1073/pnas.060099710310.1073/pnas.0600997103 ↗
43. 10.1002/btm2.1004710.1002/btm2.10047 ↗
44. 10.1021/ja208433810.1021/ja2084338 ↗
45. 10.1021/acs.molpharmaceut.7b0050710.1021/acs.molpharmaceut.7b00507 ↗
46. 10.1039/c6bm00500d10.1039/c6bm00500d ↗
47. Curtsinger J. M. · J. Immunol. · 1999 · 162 · 325610.4049/jimmunol.162.6.3256 ↗
48. Janeway C. A. · 2001
49. 10.1016/j.it.2011.01.00410.1016/j.it.2011.01.004 ↗
50. 10.1111/j.1365-2567.2005.02268.x10.1111/j.1365-2567.2005.02268.x ↗
51. 10.1021/ja803947s10.1021/ja803947s ↗
52. 10.1021/acs.molpharmaceut.8b0080210.1021/acs.molpharmaceut.8b00802 ↗
53. 10.1146/annurev-immunol-030409-10121210.1146/annurev-immunol-030409-101212 ↗
54. 10.3389/fimmu.2012.0040610.3389/fimmu.2012.00406 ↗
55. 10.1067/mai.2003.10210.1067/mai.2003.102 ↗
56. 10.1016/j.biomaterials.2014.05.06710.1016/j.biomaterials.2014.05.067 ↗
57. 10.1021/am501376n10.1021/am501376n ↗